Cargando…

Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis

Objective: The study aimed to evaluate the vancomycin and amikacin concentrations in serum and dialysate for automatic peritoneal dialysis (APD) patients. Methods: A total of 558 serum and dialysate samples of 12 episodes of gram-positive and 18 episodes of gram-negative peritonitis were included to...

Descripción completa

Detalles Bibliográficos
Autores principales: Falbo dos Reis, Pâmela, Barretti, Pasqual, Marinho, Laudilene, Balbi, Andre Luís, Awdishu, Linda, Ponce, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194258/
https://www.ncbi.nlm.nih.gov/pubmed/34122079
http://dx.doi.org/10.3389/fphar.2021.658014
_version_ 1783706382726332416
author Falbo dos Reis, Pâmela
Barretti, Pasqual
Marinho, Laudilene
Balbi, Andre Luís
Awdishu, Linda
Ponce, Daniela
author_facet Falbo dos Reis, Pâmela
Barretti, Pasqual
Marinho, Laudilene
Balbi, Andre Luís
Awdishu, Linda
Ponce, Daniela
author_sort Falbo dos Reis, Pâmela
collection PubMed
description Objective: The study aimed to evaluate the vancomycin and amikacin concentrations in serum and dialysate for automatic peritoneal dialysis (APD) patients. Methods: A total of 558 serum and dialysate samples of 12 episodes of gram-positive and 18 episodes of gram-negative peritonitis were included to investigate the relationship between vancomycin and amikacin concentrations in serum and dialysate on the first and third days of treatment. Samples were analysed 30, 120 min, and 48 h after intraperitoneal administration of vancomycin in peritonitis caused by gram-positive agents and 30, 120 min, and 24 h after intraperitoneal administration of amikacin in peritonitis caused by gram-negative agents. Vancomycin was administered every 72 h and amikacin once a day. The target therapeutic concentration of amikacin was 25–35 mg/l at the peak moment and 4–8 mg/l at the trough moment; and after 48 h for vancomycin, 15–20 mg/l at the trough moment. Results: For peritonitis caused by gram-negative agents, at the peak moment, therapeutic levels of amikacin were reached in dialysate in 80.7% of patients with evolution to cure and in 50% of patients evaluated as non-cure (p = 0.05). At the trough moment, only 38% were in therapeutic concentrations in the dialysate in the cure group and 42.8% in the non-cure group (p = 1). Peak plasma concentrations were subtherapeutic in 98.4% of the samples in the cure group and in 100% of the non-cure group. At the trough moment, therapeutic concentrations were present in 74.4% of the cure group and 71.4% of the non-cure group (p = 1). Regarding vancomycin and among gram-positive agents, therapeutic levels were reached at the peak moment in 94% of the cure group and 6% of the non-cure group (p = 0.007). After 48 h, 56.8% of the cure group had a therapeutic serum concentration whereas for the non-cure group it was only 33.3% (p = 0.39). Conclusion: Despite a small sample size, we demonstrated peak dialysate amikacin level and peak serum vancomycin level correlates well with Gram-negative and Gram positve peritonitis cure, respectively. It is suggested to study the antibiotics pharmacodynamics for a better understanding of therapeutic success in a larger sample.
format Online
Article
Text
id pubmed-8194258
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81942582021-06-12 Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis Falbo dos Reis, Pâmela Barretti, Pasqual Marinho, Laudilene Balbi, Andre Luís Awdishu, Linda Ponce, Daniela Front Pharmacol Pharmacology Objective: The study aimed to evaluate the vancomycin and amikacin concentrations in serum and dialysate for automatic peritoneal dialysis (APD) patients. Methods: A total of 558 serum and dialysate samples of 12 episodes of gram-positive and 18 episodes of gram-negative peritonitis were included to investigate the relationship between vancomycin and amikacin concentrations in serum and dialysate on the first and third days of treatment. Samples were analysed 30, 120 min, and 48 h after intraperitoneal administration of vancomycin in peritonitis caused by gram-positive agents and 30, 120 min, and 24 h after intraperitoneal administration of amikacin in peritonitis caused by gram-negative agents. Vancomycin was administered every 72 h and amikacin once a day. The target therapeutic concentration of amikacin was 25–35 mg/l at the peak moment and 4–8 mg/l at the trough moment; and after 48 h for vancomycin, 15–20 mg/l at the trough moment. Results: For peritonitis caused by gram-negative agents, at the peak moment, therapeutic levels of amikacin were reached in dialysate in 80.7% of patients with evolution to cure and in 50% of patients evaluated as non-cure (p = 0.05). At the trough moment, only 38% were in therapeutic concentrations in the dialysate in the cure group and 42.8% in the non-cure group (p = 1). Peak plasma concentrations were subtherapeutic in 98.4% of the samples in the cure group and in 100% of the non-cure group. At the trough moment, therapeutic concentrations were present in 74.4% of the cure group and 71.4% of the non-cure group (p = 1). Regarding vancomycin and among gram-positive agents, therapeutic levels were reached at the peak moment in 94% of the cure group and 6% of the non-cure group (p = 0.007). After 48 h, 56.8% of the cure group had a therapeutic serum concentration whereas for the non-cure group it was only 33.3% (p = 0.39). Conclusion: Despite a small sample size, we demonstrated peak dialysate amikacin level and peak serum vancomycin level correlates well with Gram-negative and Gram positve peritonitis cure, respectively. It is suggested to study the antibiotics pharmacodynamics for a better understanding of therapeutic success in a larger sample. Frontiers Media S.A. 2021-05-28 /pmc/articles/PMC8194258/ /pubmed/34122079 http://dx.doi.org/10.3389/fphar.2021.658014 Text en Copyright © 2021 Falbo dos Reis, Barretti, Marinho, Balbi, Awdishu and Ponce. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Falbo dos Reis, Pâmela
Barretti, Pasqual
Marinho, Laudilene
Balbi, Andre Luís
Awdishu, Linda
Ponce, Daniela
Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis
title Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis
title_full Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis
title_fullStr Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis
title_full_unstemmed Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis
title_short Pharmacokinetics of Intraperitoneal Vancomycin and Amikacin in Automated Peritoneal Dialysis Patients With Peritonitis
title_sort pharmacokinetics of intraperitoneal vancomycin and amikacin in automated peritoneal dialysis patients with peritonitis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8194258/
https://www.ncbi.nlm.nih.gov/pubmed/34122079
http://dx.doi.org/10.3389/fphar.2021.658014
work_keys_str_mv AT falbodosreispamela pharmacokineticsofintraperitonealvancomycinandamikacininautomatedperitonealdialysispatientswithperitonitis
AT barrettipasqual pharmacokineticsofintraperitonealvancomycinandamikacininautomatedperitonealdialysispatientswithperitonitis
AT marinholaudilene pharmacokineticsofintraperitonealvancomycinandamikacininautomatedperitonealdialysispatientswithperitonitis
AT balbiandreluis pharmacokineticsofintraperitonealvancomycinandamikacininautomatedperitonealdialysispatientswithperitonitis
AT awdishulinda pharmacokineticsofintraperitonealvancomycinandamikacininautomatedperitonealdialysispatientswithperitonitis
AT poncedaniela pharmacokineticsofintraperitonealvancomycinandamikacininautomatedperitonealdialysispatientswithperitonitis